search
Back to results

Effects of Nefopam on Hyperalgesia After Cardiac Surgery (NefalCard)

Primary Purpose

Hyperalgesia, Pain, Postoperative, Pain, Chronic Disease

Status
Completed
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Nefopam
néfopam
Placebo comparator
Sponsored by
University Hospital, Bordeaux
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hyperalgesia focused on measuring Postoperative Hyperalgesia, cardiac Surgical Procedures, Nefopam, Randomized Controlled Trials, Pain and chronic disease

Eligibility Criteria

55 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 55-75 years old
  • ASA score: 1-3
  • Patients scheduled for Cardiac surgery with median sternotomy for : single valve replacement or Bentall or Benson or Tyron David surgery, single or multiple Cardiac Artery Bypass Grafting (CABG) , combined surgery (valve replacement + CABG) without preoperative risk of postoperative complications
  • Informed consent obtained from the patient

Exclusion Criteria:

  • Drug or alcohol abuse history
  • Analgesic or opioid consumption within the 12hs preceding the surgery
  • Chronic use of analgesic drugs or history of chronic pain
  • Convulsion or epilepsy history
  • Glaucoma history
  • Disability to understand morphine PCA use
  • Allergy to nefopam

Sites / Locations

  • Département d'Anesthésie-Réanimation II - Hôpital cardiologique - Groupe Hospitalier Sud, CHU de Bordeaux - 4, Av de Magellan

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

1

2

3

Arm Description

nefopam infusion will start before the surgical incision, at the induction time of anesthesia and will be continued until postoperative H48

nefopam administration will start at the end of the surgery and will be continued until postoperative H48

control group that will receive a placebo from the induction time of anesthesia until H48

Outcomes

Primary Outcome Measures

Nociceptive threshold evaluated with Von Frey mechanical dynamic stimulation. This will start 10cm far from the wound on a perpendicular line to the wound and will be conducted by 1cm step to the wound until the patient explains the stimulation

Secondary Outcome Measures

static hyperalgesia with Von Frey stimulation 1cm far from the middle of the wound, on the right side of the wound.
Morphine consumption
Pain scores evaluation
Cognitive functions evaluation

Full Information

First Posted
December 18, 2006
Last Updated
May 27, 2010
Sponsor
University Hospital, Bordeaux
search

1. Study Identification

Unique Protocol Identification Number
NCT00413257
Brief Title
Effects of Nefopam on Hyperalgesia After Cardiac Surgery
Acronym
NefalCard
Official Title
Study of the Effects of Nefopam on Hyperalgesia Following Sternotomy in Cardiac Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
May 2010
Overall Recruitment Status
Completed
Study Start Date
December 2006 (undefined)
Primary Completion Date
December 2007 (Actual)
Study Completion Date
November 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University Hospital, Bordeaux

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Postoperative pain after major surgery is consecutive not only to the nociceptive inputs coming from the surgical lesion, but also to peripheral and central neuronal sensitization. This lead to postoperative hyperalgesia and allodynia that are enhanced by the per operative use of high opioid doses. Anti-NMDA drugs have been reported as able to reduce this sensitization process and then to decrease acute morphine tolerance during the postoperative period. Nefopam has been lately shown to combine in experimental trials analgesic and anti hyperalgesic effects. The aim of this study is to compare anti-hyperalgesic effects of nefopam given either before incision and continuously for the following 48hours or starting from the end of the surgery and given for 48hours to a control group that would receive placebo for 48hours. Postoperative analgesia will be based on morphine PCA. Pain scores, hyperalgesia, allodynia, postoperative morphine consumption, and development of chronic pain will be the main criteria that will be evaluated during this study
Detailed Description
Introduction : Postoperative pain is not only a consequence of the surgical lesion, but is also related to sensitization processes that appear in peripheral and central nerves. This sensitization induce clinically hyperalgesia and allodynia. From an experimental viewpoint it comes mainly from a central activation of NMDA receptors in neurons that conduct the nociceptive message. Recent studies have shown that high-dose opioids were able, via NMDA receptors, to enhance postoperative hyperalgesia and to increase pain scores and morphine consumption after surgery. Nevertheless per operative use of opioid is still necessary to avoid per operative stress and systemic consequence of the surgical stimulation. Some drugs (ketamine, nitrous oxide…) succeeded in reducing postoperative hyperalgesia and pains scores and acute morphine tolerance. They also were able to decrease pain chronicization. Nefopam, well known as an analgesic since the 80's, presents both analgesic and anti hyperalgesic properties as lately demonstrated in experimental trials. Nevertheless these anti hyperalgesic properties have never been evaluated in humans scheduled for cardiac surgery. Nefopam administration could reduce acute morphine tolerance and could enhance postoperative pain management by reducing sensitization processes and hyperalgesia. Objective : The main purpose of this clinical trial will be to evaluate in patients scheduled for cardiac surgery with sternotomy the nefopam effects on the nociceptive threshold evaluated with dynamic Von Frey mechanical stimulation. The secondary objectives will evaluate static hyperalgesia, postoperative pain scores, morphine consumption, cognitive functions, and development of chronic pain and dysesthesia. Methods : Prospective, randomized, double-blind study that will compare three parallel groups that will receive the same per operative anesthesia except for the nefopam doses. Group 1: nefopam infusion will start before the surgical incision, at the induction time of anesthesia and will be continued until postoperative H48. Group 2: nefopam administration will start at the end of the surgery and will be continued until postoperative H48. Group 3: control group that will receive a placebo from the induction time of anesthesia until H48. All patients will receive postoperatively morphine infusion following the Patient Controlled Analgesia concept. Number of patients to be included : 90 Duration of the study : 2 years Start : second semester of 2006 Expected result : Reduction of the extend of hyperalgesia around the wound evaluated with dynamic Von Frey mechanical stimulation more than 20%.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hyperalgesia, Pain, Postoperative, Pain, Chronic Disease
Keywords
Postoperative Hyperalgesia, cardiac Surgical Procedures, Nefopam, Randomized Controlled Trials, Pain and chronic disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
90 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
nefopam infusion will start before the surgical incision, at the induction time of anesthesia and will be continued until postoperative H48
Arm Title
2
Arm Type
Experimental
Arm Description
nefopam administration will start at the end of the surgery and will be continued until postoperative H48
Arm Title
3
Arm Type
Placebo Comparator
Arm Description
control group that will receive a placebo from the induction time of anesthesia until H48
Intervention Type
Drug
Intervention Name(s)
Nefopam
Intervention Description
0,3mg/kg IV bolus preoperative and 65 µg/kg/h during H48 postoperative
Intervention Type
Drug
Intervention Name(s)
néfopam
Intervention Description
bolus Néfopam (0,3mg/kg) during 10 min at the end of surgery and 65 µg/kg/h during postoperative H48
Intervention Type
Drug
Intervention Name(s)
Placebo comparator
Intervention Description
bolus NaCl during 10 min at the end of surgery and during postoperative H48
Primary Outcome Measure Information:
Title
Nociceptive threshold evaluated with Von Frey mechanical dynamic stimulation. This will start 10cm far from the wound on a perpendicular line to the wound and will be conducted by 1cm step to the wound until the patient explains the stimulation
Time Frame
H 24
Secondary Outcome Measure Information:
Title
static hyperalgesia with Von Frey stimulation 1cm far from the middle of the wound, on the right side of the wound.
Time Frame
1, 2, 4 and 7 days after intervention
Title
Morphine consumption
Time Frame
over the 48 H postoperative
Title
Pain scores evaluation
Time Frame
Acute pain (1, 2, 4 and 7 days after intervention) / Chronic Pain (3, 6 and 12 month)
Title
Cognitive functions evaluation
Time Frame
1, 2, 4 and 7 days after intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 55-75 years old ASA score: 1-3 Patients scheduled for Cardiac surgery with median sternotomy for : single valve replacement or Bentall or Benson or Tyron David surgery, single or multiple Cardiac Artery Bypass Grafting (CABG) , combined surgery (valve replacement + CABG) without preoperative risk of postoperative complications Informed consent obtained from the patient Exclusion Criteria: Drug or alcohol abuse history Analgesic or opioid consumption within the 12hs preceding the surgery Chronic use of analgesic drugs or history of chronic pain Convulsion or epilepsy history Glaucoma history Disability to understand morphine PCA use Allergy to nefopam
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philippe RICHEBE, Dr
Organizational Affiliation
University Hospital, Bordeaux
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Antoine BENARD, Dr
Organizational Affiliation
University Hospital, Bordeaux
Official's Role
Study Chair
Facility Information:
Facility Name
Département d'Anesthésie-Réanimation II - Hôpital cardiologique - Groupe Hospitalier Sud, CHU de Bordeaux - 4, Av de Magellan
City
Pessac
ZIP/Postal Code
33604
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
23063945
Citation
Richebe P, Picard W, Rivat C, Jelacic S, Branchard O, Leproust S, Cahana A, Janvier G. Effects of nefopam on early postoperative hyperalgesia after cardiac surgery. J Cardiothorac Vasc Anesth. 2013 Jun;27(3):427-35. doi: 10.1053/j.jvca.2012.08.015. Epub 2012 Oct 12.
Results Reference
derived

Learn more about this trial

Effects of Nefopam on Hyperalgesia After Cardiac Surgery

We'll reach out to this number within 24 hrs